310 related articles for article (PubMed ID: 30759772)
1. Pharmacological Reactivation of the Silenced
Kumari D; Gazy I; Usdin K
Brain Sci; 2019 Feb; 9(2):. PubMed ID: 30759772
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome.
Tabolacci E; Palumbo F; Nobile V; Neri G
Genes (Basel); 2016 Aug; 7(8):. PubMed ID: 27548224
[TBL] [Abstract][Full Text] [Related]
3. CGG-repeat dynamics and
Zhou Y; Kumari D; Sciascia N; Usdin K
Mol Autism; 2016; 7():42. PubMed ID: 27713816
[TBL] [Abstract][Full Text] [Related]
4. Targeted Reactivation of
Haenfler JM; Skariah G; Rodriguez CM; Monteiro da Rocha A; Parent JM; Smith GD; Todd PK
Front Mol Neurosci; 2018; 11():282. PubMed ID: 30158855
[TBL] [Abstract][Full Text] [Related]
5. Molecular Biomarkers in Fragile X Syndrome.
Zafarullah M; Tassone F
Brain Sci; 2019 Apr; 9(5):. PubMed ID: 31035599
[TBL] [Abstract][Full Text] [Related]
6. Small Molecules Targeting H3K9 Methylation Prevent Silencing of Reactivated
Kumari D; Sciascia N; Usdin K
Genes (Basel); 2020 Mar; 11(4):. PubMed ID: 32230785
[TBL] [Abstract][Full Text] [Related]
7. Modeling fragile X syndrome in the Fmr1 knockout mouse.
Kazdoba TM; Leach PT; Silverman JL; Crawley JN
Intractable Rare Dis Res; 2014 Nov; 3(4):118-33. PubMed ID: 25606362
[TBL] [Abstract][Full Text] [Related]
8. A Genotype-Phenotype Study of High-Resolution
Budimirovic DB; Schlageter A; Filipovic-Sadic S; Protic DD; Bram E; Mahone EM; Nicholson K; Culp K; Javanmardi K; Kemppainen J; Hadd A; Sharp K; Adayev T; LaFauci G; Dobkin C; Zhou L; Brown WT; Berry-Kravis E; Kaufmann WE; Latham GJ
Brain Sci; 2020 Sep; 10(10):. PubMed ID: 33008014
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome.
Xie N; Gong H; Suhl JA; Chopra P; Wang T; Warren ST
PLoS One; 2016; 11(10):e0165499. PubMed ID: 27768763
[TBL] [Abstract][Full Text] [Related]
10. FMRP Levels in Human Peripheral Blood Leukocytes Correlates with Intellectual Disability.
Roth M; Ronco L; Cadavid D; Durbin-Johnson B; Hagerman RJ; Tassone F
Diagnostics (Basel); 2021 Sep; 11(10):. PubMed ID: 34679478
[TBL] [Abstract][Full Text] [Related]
11. microRNAs and Fragile X Syndrome.
Lin SL
Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.
Brasa S; Mueller A; Jacquemont S; Hahne F; Rozenberg I; Peters T; He Y; McCormack C; Gasparini F; Chibout SD; Grenet O; Moggs J; Gomez-Mancilla B; Terranova R
Clin Epigenetics; 2016; 8():15. PubMed ID: 26855684
[TBL] [Abstract][Full Text] [Related]
13. Modeling Fragile X Syndrome in
Drozd M; Bardoni B; Capovilla M
Front Mol Neurosci; 2018; 11():124. PubMed ID: 29713264
[TBL] [Abstract][Full Text] [Related]
14. Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27.
Kumari D; Usdin K
Hum Mol Genet; 2016 Sep; 25(17):3689-3698. PubMed ID: 27378697
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of FMR1 gene expression is a promising strategy for fragile X syndrome therapy.
Shitik EM; Velmiskina AA; Dolskiy AA; Yudkin DV
Gene Ther; 2020 Jun; 27(6):247-253. PubMed ID: 32203197
[TBL] [Abstract][Full Text] [Related]
16. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
[TBL] [Abstract][Full Text] [Related]
17. Clinical, molecular, and pharmacological aspects of FMR1 related disorders.
Pugin A; Faundes V; Santa María L; Curotto B; Aliaga S; Salas I; Soto P; Bravo P; Peña MI; Alliende MA
Neurologia; 2017 May; 32(4):241-252. PubMed ID: 25529181
[TBL] [Abstract][Full Text] [Related]
18. Fmr1 deficiency promotes age-dependent alterations in the cortical synaptic proteome.
Tang B; Wang T; Wan H; Han L; Qin X; Zhang Y; Wang J; Yu C; Berton F; Francesconi W; Yates JR; Vanderklish PW; Liao L
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):E4697-706. PubMed ID: 26307763
[TBL] [Abstract][Full Text] [Related]
19. Incomplete silencing of full mutation alleles in males with fragile X syndrome is associated with autistic features.
Baker EK; Arpone M; Aliaga SM; Bretherton L; Kraan CM; Bui M; Slater HR; Ling L; Francis D; Hunter MF; Elliott J; Rogers C; Field M; Cohen J; Cornish K; Santa Maria L; Faundes V; Curotto B; Morales P; Trigo C; Salas I; Alliende AM; Amor DJ; Godler DE
Mol Autism; 2019; 10():21. PubMed ID: 31073396
[TBL] [Abstract][Full Text] [Related]
20. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
